T Cell Editing Composition for Targeted TRAC CAR Integration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for modifying T cells into CAR-T cells face challenges such as low transduction efficiency, random genomic integration, high cell death rates, and mutagenesis risks, particularly when using viral vectors and electroporation, limiting their clinical application, especially for primary T cells.
Innovation Solution
A composition comprising a protein complex with a polynucleotide-modifying enzyme domain, a T cell membrane binding domain, and an endosome escape domain, along with a guide oligonucleotide targeting the TRAC gene, is used to introduce a chimeric antigen receptor (CAR) into T cells, ensuring precise genomic editing and integration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If viral vectors (lentiviral or retroviral) are used for CAR gene editing, then the method is safer with lower genotoxicity, but the transduction efficiency in primary T cells remains low
Solution Approach 1:
The patent employs a protein complex as an intermediary delivery vehicle that mediates between the CAR gene construct and primary T cells. This protein complex includes a polynucleotide-modifying enzyme domain (e.g., Cas9), a T cell membrane binding domain (e.g., targeting CD3, CD4, or CD8), and an endosome escape domain. The complex binds to the T cell membrane, facilitates internalization, and delivers the CAR construct directly to the cytoplasm, achieving high transduction efficiency (75-95%) without requiring viral integration, thus maintaining safety.
2Reliability
If electroporation is used to deliver gene editing material, then the method is non-viral and avoids integration risks, but the cell death rate is high
Solution Approach 1:
The protein complex serves as a non-viral intermediary that avoids the need for electroporation's harsh physical fields. Instead of using electrical pulses that damage cell membranes, the protein complex naturally binds to T cell surfaces via membrane binding domains, facilitates gentle internalization through endocytosis, and escapes endosomes to deliver genetic material, achieving high transduction efficiency with minimal cell death.
3Ease of manufacture
If random genomic integration methods are used, then the process is simple, but off-target effects and insertional mutagenesis occur
Solution Approach 1:
The patent applies local quality by directing the polynucleotide-modifying enzyme to a specific target locus (TRAC gene) within the T cell genome through guide oligonucleotides. This ensures precise, targeted integration of the CAR construct at the intended location rather than random integration anywhere in the genome, eliminating off-target effects and insertional mutagenesis while maintaining process simplicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances transduction efficiency and targeting specificity, reducing off-target effects and cell death, thereby improving the efficacy of CAR-T cell therapies, particularly for cancer treatment.
Implementation Method 1
The protein complex comprises a polynucleotide-modifying enzyme domain, a T cell membrane binding domain and an endosome escape domain
Implementation Method 2
a guide oligonucleotide specific to a T cell receptor a constant (TRAC) gene of the T cell; and a donor DNA comprising two homology arms at each end of the donor DNA homologous to exon1 of the TRAC gene
Implementation Method 3
a protein complex comprising a polynucleotide-modifying enzyme domain, a T cell membrane binding domain and an endosome escape domain
Data Source
AI summary
There is provided a composition for modifying a T cell, the composition comprising: a protein complex comprising a polynucleotide-modifying enzyme domain, a T cell membrane binding domain and an endosome escape domain; a guide oligonucleotide specific to a T cell receptor constant (TRAC) gene of the T cell; and a donor DNA comprising two homology arms at each end of the donor DNA homologous to exon1 of the TRAC gene and encoding therebetween a chimeric antigen T cell receptor comprising: translocation signal for translocation to a cell membrane of the T cell; a transmembrane domain; an intracellular signaling domain; and an extracellular antigen binding domain.